Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Afternoon Krone,
“So I would look out for the CHK1 at our 3Q update. ”
I maybe reading into something that’s not there…. However, that sentence “I would look out for the CHK1” is suggesting there is going to be a chk1 in the Q3 update ????
Utah- that’s a very interesting question. They may well say that not long ago the sp was 0.25p and rose to 9.5p or to make it easy for you, if you invested £10k you could have sold out the same investment for £380k. Now Utah, based on your suggestion the BoD have no business acumen, one would assume you have far more. So surely as a LTH this is what you did? Can you ask anymore from the BOD? Just a thought.
Colbatblue, my answer would be a placing. However that’s not necessarily always a bad thing is it? I would happy to accept a 25% dilution if the result was funding P2. If successful this would result in many multiple increase in the SP.
Colbatblue, everything you say is true. Thanks for sharing. I just hope those silly HNWI are reading this,!it’s such a shame they didn’t have someone like you to guide them, the world is so unfair.
Once again thanks for sharing your knowledge with the BB. I’m guessing you’re not invested here (why would you be) which makes the sharing of your knowledge so much more generous. Thumbs up from me.
As its a bit of a slow news day I thought i would have a look at who the likely organisation is that Saruem are working "alongside with". Ref latest RNS.
"Sareum, working alongside a specialist contract research organisation (CRO). The CRO conducting and managing the studies has extensive experience in conducting trials in inflammatory diseases and will recruit up to 120 subjects at a site in Manchester, UK."
My reckoning is that they are working with Manchester Clinical Trials Unit.
https://www.bmh.manchester.ac.uk/research/manchester-ctu/
Which states "We are home to a number of centres of excellence, including those funded by charities and industry. "
https://www.mccir.manchester.ac.uk/research/
Of particular relevance would be: https://www.mccir.manchester.ac.uk/research/areas/skin-inflammation/
This would certainly fit and the use of the word "organisation" would indicate its a larger group they are working alongside.
Morning Stoney, ref your last sentence.
I think that’s exactly what Tim is suggesting:
“Sareum believes that TYK2/JAK1 inhibition offers potential for increased efficacy in psoriasis, compared with existing approved therapies.”
All good.
With regards to the bloomberg article "GSK Poaches Top AstraZeneca Dealmakers to Boost Drug Pipeline"
"Garrett Rhyasen has also started at GSK this month as vice president of oncology search and evaluation. Rhyasen had been at AstraZeneca about three years, most recently leading the business development team’s global search and evaluation efforts in oncology, according to LinkedIn. "
Garrett published an article back in 2015 which listed Sareum in the Chk1 competitive landscape. If nothing else he should certainly be aware of Sareum.
http://oncologydiscovery.com/2015/08/08/strategies-to-enhance-patient-responses-to-checkpoint-inhibitors/
https://www.bloomberg.com/news/articles/2022-06-29/gsk-poaches-astrazeneca-s-sheldon-for-business-development-role
Ashpot, as others have said, stay positive. Sounds like it’s been a quick response from diagnosis to treatment, which as I’m sure you’re away is extremely important and a very positive action. All the very best to you and your wife.
Warthog. The biggest purchase most people make is when they buy a home (if they are indeed lucky enough to be able to get on the property ladder). No one is really privileged as to what the property market will do, it might crash it might boom?
Comparing it to getting on a commercial aircraft and hoping the pilot has received the correct training is hardly a grown up comparison.
Are we off to Button Moon ?
https://m.youtube.com/watch?v=f20BLJGHNXY
Pfizer, Roivant Unveil Priovant with High Potential TYK2/JAK1 Inhibitor
https://www.fiercebiotech.com/biotech/mystery-solved-roivant-pfizers-tyk2-partner-and-cutting-other-programs-fund-late-phase